<DOC>
	<DOCNO>NCT01917760</DOCNO>
	<brief_summary>The purpose study determine upon administer GABA orally person absorb , distribute , well drug 's pharmacological effect body glucose level , serum C-peptide and/or insulin level ( refer pharmacokinetics/pharmacodynamics ) . We conduct experiment normal subject address question .</brief_summary>
	<brief_title>Pharmacokinetics Study Gamma-aminobutyric Acid</brief_title>
	<detailed_description>Type 1 diabetes autoimmune disease result progressive loss pancreatic insulin-secreting beta-cells . This consequently lead lack insulin elevation blood sugar , namely hyperglycemia , major cause development diabetes acute chronic complication . The current treatment type 1 diabetes require life-long dependency daily insulin injection , cause inconvenience burden patient . Drug-induced hypoglycemia also common present major challenge insulin therapy . Furthermore , although insulin therapy lifesaving , cure neither reverse progression disease prevents development serious complication associate disease . New treatment urgently need . Recent study demonstrate natural chemical find brain , gamma-aminobutyric acid ( GABA ) , also produce large quantity pancreatic beta-cells , beta-cell regenerative immunoregulatory effect . Importantly , GABA prevent partially reverse diabetes type 1 diabetes mouse model . It important address essential question regard potential effect GABA diabetic patient human . Given largely unknown mechanism action GABA pancreas , limited information GABA absorb , distribute eliminate human body , plan examine issue ( referred pharmacokinetics/pharmacodynamics ) normal subject . The outcome study provide useful information mechanism action GABA human subject .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>1 . Volunteers good health condition 19 40 year age ( inclusive ) time sign informed consent . 2 . Body mass index ( BMI ) 18.5 24 kg/m2 ( inclusive ) , weight great 50 kg . 3 . Not medication 2 week screen . 4 . No blood donation within 3 month screen . 5 . Must sign inform consent . Note : Blood biochemical test must normal screening . However , participant 's testresults beyond normal range , individual still recruit long result affect experiment . 1 . Abnormalities physical examination , laboratory test , ECG screening , may influence result study . 2 . Previous exist history severe heart , liver , kidney , gastrointestinal , nervous system , mental , metabolic abnormality well disease affect drug absorption , circulation , metabolism , excretion . 3 . History alcoholism , smoking , drug abuse within past 1 year . 4 . Participation clinical drug study within past 30 day . 5 . Any definite suspect allergy family history allergy GABA similar drug .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Gamma-aminobutyric acid</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Insulin</keyword>
	<keyword>C-peptide</keyword>
	<keyword>Glucagon</keyword>
</DOC>